Buccal mucosa and gingivobuccal cancer (oral cancer in India)
Cancer of the cheek lining and gums is India's commonest cancer in men, caused by chewing tobacco and areca nut. Surgery with reconstruction is the mainstay, and trials from Tata Memorial in Mumbai have shown that removing the neck nodes up front, cheap oral chemotherapy, tiny doses of immunotherapy and visual screening by health workers all save lives at low cost.
Overview
Squamous cell carcinoma of the buccal mucosa, gingivobuccal sulcus, lower alveolus and retromolar trigone is the characteristic oral cancer of South Asia, where smokeless tobacco (gutka, khaini, mawa) and areca nut are held against the cheek for hours a day. It is often preceded by leukoplakia or by oral submucous fibrosis, the areca-nut induced stiffening of the cheek that limits mouth opening and hides tumours. The Kerala trial, reported by Sankaranarayanan in 2005, showed that visual oral examination by trained health workers cut oral cancer deaths in tobacco or alcohol users by about a third, the only randomised evidence for oral cancer screening.
Surgery is the mainstay: wide excision with marginal or segmental mandibulectomy for bone involvement, clearance of the infratemporal fossa when the masticator space is involved, neck dissection and free-flap reconstruction with anterolateral thigh or fibula flaps. The Tata Memorial trial of elective neck dissection, reported by D'Cruz in 2015 in 596 patients with early node-negative oral cancer, showed three-year overall survival of 80.0 against 67.5 percent, and Tata Memorial surgeons have redefined which tumours invading the masticator space can still be resected; induction docetaxel-cisplatin-fluorouracil is used to make borderline tumours operable. Postoperative radiotherapy or cisplatin chemoradiation follows for advanced stage, extranodal extension or positive margins.
Because most Indian patients present late and few can afford imported drugs, Tata Memorial trials have built a low-cost palliative pathway: oral methotrexate with celecoxib beat intravenous cisplatin (median survival 7.5 against 6.1 months, with fewer serious side effects); adding nivolumab at one-twentieth of the usual dose raised one-year survival from 16.3 to 43.4 percent; and METRO PLUS in Varanasi doubled median survival from 5 to 10 months by adding metronomic tablets to paclitaxel-carboplatin. Tobacco control, state bans on gutka and screening are the levers for prevention, and incidence is still rising.
State of the art
- Tata Memorial trials have produced category 1 evidence for elective neck dissection and the only randomised evidence for oral cancer screening.
- Low-cost metronomic chemotherapy and low-dose immunotherapy are now standards for palliative care across South Asia.
- Compartment surgery and free-flap reconstruction have made resection of masticator-space tumours possible.
Red cards
From the labels and guidelines behind the standard of care. Your team's thresholds win.- Emergency services nowBleeding or bruising
Bleeding that will not stop, black or bloody stools, or unexplained bruising when platelets are expected to be low.
- Emergency services nowHypophysitis or adrenal crisis
Persistent headache with extreme tiredness, nausea, dizziness on standing or low blood pressure. Vomiting, severe weakness or collapse is adrenal crisis.
- Emergency services nowBlood clot (lenalidomide, pomalidomide, thalidomide)
A swollen painful calf, or sudden breathlessness with chest pain; venous and arterial thromboembolism is a boxed warning and blood-thinning prophylaxis is recommended.
- Check before combiningFood and drink: Fluorouracil (5-FU)
Capecitabine: take within 30 minutes after a meal. DPD deficiency (DPYD variants) causes severe toxicity: pre-treatment genotyping is recommended in Europe.
- Check before combiningFood and drink: Pembrolizumab
No pharmacokinetic interactions expected (antibody). See the irAE guide for toxicity management.
- Check before combiningKidneys: Cisplatin
Dose reduce or avoid for CrCl below 60 (carboplatin is the alternative).
See all on the product pages:CisplatinDocetaxelFluorouracil (5-FU)MethotrexateNivolumabPembrolizumab·Printable cards in the navigator
Anatomy and lymph node drainage
- Oral cavity and tongue
- Oropharynx: tonsil, base of tongue (HPV)
- Nasopharynx (EBV)
- Larynx and hypopharynx
- Parotid and other salivary glands
- Thyroid
- Nodes: level I (submandibular)
- Nodes: level II (upper jugular)
- Nodes: level III-IV (jugular)
- Nodes: level V (posterior)
- Nodes: level VI (central, thyroid)
- Nodes: retropharyngeal (nasopharynx)
Site decides cause and behaviour: HPV drives oropharyngeal cancer, EBV drives nasopharyngeal cancer, tobacco drives oral and laryngeal cancer; all drain into the neck node levels that surgeons and radiotherapists map.
- Oral cavity and tongueCancer arising in oral submucous fibrosis (areca nut)
- Oropharynx: tonsil, base of tongue (HPV)
- Nasopharynx (EBV)
- Larynx and hypopharynx
- Parotid and other salivary glands
- ThyroidRetromolar trigone cancer
- level I (submandibular)
- level II (upper jugular)
- level III-IV (jugular)
- level V (posterior)
- level VI (central, thyroid)
- retropharyngeal (nasopharynx)
Same organ: Oropharyngeal cancer (tonsil and base of tongue), Laryngeal and hypopharyngeal cancer, Oral cavity cancer (mouth and tongue), Head and neck squamous cell carcinoma, Nasopharyngeal carcinoma, Salivary gland cancers, Papillary thyroid cancer, Follicular thyroid cancer, Medullary thyroid cancer, Anaplastic thyroid cancer, Thyroid cancer, Nasal cavity and paranasal sinus cancers (including esthesioneuroblastoma), NUT carcinoma (midline carcinoma with NUTM1 rearrangement), Parathyroid carcinoma, Multiple endocrine neoplasia syndromes (MEN1, MEN2, MEN4), HPV-positive oropharyngeal cancer, HPV-negative head and neck squamous cell carcinoma (including HPV-negative oropharyngeal cancer), Recurrent or metastatic head and neck squamous cell carcinoma, Hypopharyngeal cancer, Adenoid cystic carcinoma, Salivary duct carcinoma, Mucoepidermoid carcinoma, Oral tongue and floor of mouth cancer, Lip cancer
India carries about a third of the world's oral cancers, and the gingivobuccal complex (the cheek lining, the gums and the sulcus between them) is the commonest site there because chewed tobacco and areca nut sit in the cheek pouch; it is the leading cancer in Indian men.
- Oral cancer visual screeningEstablished
Nothing recorded yet.
Also on OnCo: Symptoms and red flags · Early detection roadmap.
Cases by country
No country-level case numbers. This cancer is not mapped to a GLOBOCAN site.
One section per setting: the options named, what each is for, the trials behind them, the recorded trade-offs and the questions to ask.
Visual oral examination by trained health workers for tobacco and alcohol users (Kerala trial); treatment of leukoplakia and management of oral submucous fibrosis.
Wide excision with marginal or segmental mandibulectomy as needed, elective or therapeutic neck dissection (Tata Memorial trial), and free-flap reconstruction.
Induction docetaxel-cisplatin-fluorouracil to shrink technically unresectable tumours, then surgery in responders (Tata Memorial practice); chemoradiation otherwise.
Postoperative radiotherapy for advanced stage, perineural invasion or nodes; cisplatin chemoradiation for extranodal extension or positive margins.
Oral metronomic methotrexate with celecoxib; low-dose nivolumab added where affordable; metronomic tablets with paclitaxel-carboplatin (METRO PLUS); pembrolizumab where available.
Smokeless tobacco and areca nut cessation, gutka bans, and oral screening in high-risk people.
Subtypes & biomarkers
top- Buccal mucosa squamous cell carcinoma
- Gingivobuccal sulcus and lower alveolus (gum) cancer
- Retromolar trigone cancer
- Cancer arising in oral submucous fibrosis (areca nut)
- Verrucous carcinoma of the buccal mucosa
- Depth of invasion and bone invasion (marginal versus segmental mandibulectomy)
- Masticator space involvement (resectability)
- Extranodal extension and margin status
- Oral submucous fibrosis and leukoplakia (precursors)
- TP53 mutation
- PD-L1 combined positive score (recurrent disease)
How often this target appears
- 1941Tata Memorial Hospital opens in Bombay
- 2005Kerala trial: visual screening cuts oral cancer deaths in high-risk people
- 2015Elective neck dissection improves survival in early oral cancer
- 2020Oral metronomic methotrexate-celecoxib beats cisplatin
- 2023Low-dose nivolumab nearly triples one-year survival
- 2026METRO PLUS: metronomic tablets with paclitaxel-carboplatin double survival
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
All 14 changes by month →- 2026-09-17This recordBuccal mucosa and gingivobuccal cancer (oral cancer in India)Facts on this page last checked
When this page itself was last checked or edited.
- 2026Trial resultMETRO PLUS (Tata Memorial Centre, Varanasi)METRO PLUS (Tata Memorial Centre, Varanasi) reported
Median OS 10 vs 5 months, HR 0.
- 2026MilestoneMETRO PLUS (Tata Memorial Centre, Varanasi)METRO PLUS: metronomic tablets with paclitaxel-carboplatin double survival
A milestone in how this cancer is treated.
- 2025Trial resultNIVOPOSTOP (GORTEC 2018-01)NIVOPOSTOP (GORTEC 2018-01) reported
Three-year disease-free survival 63.
- 2023Trial resultLow-dose nivolumab plus metronomic chemotherapy (Tata Memorial)Low-dose nivolumab plus metronomic chemotherapy (Tata Memorial) reported
1-year OS 43.
- 2023MilestoneLow-dose nivolumab plus metronomic chemotherapy (Tata Memorial)Low-dose nivolumab nearly triples one-year survival
A milestone in how this cancer is treated.
What is in development for Buccal mucosa and gingivobuccal cancer (oral cancer in India), drawn from the whole corpus: 6 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Trials reported · 6
- Low-dose nivolumab plus metronomic chemotherapy (Tata Memorial) · phase 3 · 2023 · positive
- METRO PLUS (Tata Memorial Centre, Varanasi) · phase 3 · 2026 · positive
- NIVOPOSTOP (GORTEC 2018-01) · phase 3 · 2025 · positive
- Elective vs therapeutic neck dissection in node-negative oral cancer (Tata Memorial) · phase 3 · 2015 · positive
- Kerala oral cancer visual screening trial (Trivandrum) · phase 3 · 2005 · positive
- Oral metronomic chemotherapy vs intravenous cisplatin (Tata Memorial) · phase 3 · 2020 · positive
Open problems and what is being done
Late presentation and rising incidence as areca nut and gutka use spread.
and how the field plans to fix it →What is being done about thisFinding cancer earlierAvailable now- Oral cancer visual screeningEstablished
In trialsIdeas and roadmapsNothing recorded yet.
Also on OnCo: Symptoms and red flags · Early detection roadmap.
Access to pembrolizumab, cetuximab and radiotherapy machines outside big cities.
and how the field plans to fix it →What is being done about thisCost and accessAvailable nowNothing recorded yet.
In trialsIdeas and roadmapsNothing recorded yet.
Also on OnCo: Financial help · Coverage by country · HTA decisions.
Whether low-dose immunotherapy matches full-dose treatment.
Trismus and eating after cheek and jaw resection.
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Landmark trials
Expert centres
topExpert centres
Baltimore · cancer center | United States | 0 | 2,955 | 41,449 | #10 | ||
Mumbai · cancer center | India | none recorded | 4 | 665 | 4,926 | none recorded | #80 |
Varanasi · cancer center | India | none recorded | 1 | 0 | 0 | - | |
Lyon · government | France | none recorded | 1 | not matched | - | none recorded | - |
Bethesda, MD · government | United States | none recorded | 0 | 2,905 | 47,715 | - | |
Utrecht · cancer center | Netherlands | none recorded | 0 | 1,422 | 20,323 | - | |
Tianjin · cancer center | China | none recorded | 0 | 1,219 | 11,455 | - | |
Hangzhou · cancer center | China | none recorded | 0 | 1,219 | 17,635 | - | |
Rozzano (Milan) · hospital | Italy | none recorded | 0 | 1,031 | 10,720 | - | |
Naples · cancer center | Italy | none recorded | 0 | 961 | 15,028 | - | |
Changsha · cancer center | China | none recorded | 0 | 930 | 14,477 | - | |
Jinan · cancer center | China | none recorded | 0 | 920 | 7,804 | - | |
Dresden · cancer center | Germany | none recorded | 0 | 728 | 7,984 | - | |
| United Kingdom | none recorded | 0 | 693 | 7,168 | - | ||
Aarhus · hospital | Denmark | none recorded | 0 | 624 | 4,497 | - |
These are the things we can measure; they are not a ranking of quality. Each column is a field on the institution record or a count over what OnCo has linked; a centre that treats many patients with Buccal mucosa and gingivobuccal cancer but is thinly recorded here will look small.
Not known: OnCo holds no case-volume or outcome figures for centres, so none are shown. Where a national audit or registry publishes them, the centre's page links to it. Default order: Newsweek rank, then trials for this cancer, then research output.
Questions to ask
topQuestions to ask your oncologist about Buccal mucosa and gingivobuccal cancer
Newly diagnosed
- What is my exact diagnosis, stage, and grade, and which tests established them?Why: Everything else follows from an accurate stage and subtype.
- Which biomarkers have been tested on my tumour (for example Depth of invasion and bone invasion, Masticator space involvement, Extranodal extension and margin status, Oral submucous fibrosis and leukoplakia, TP53 mutation), and what were the results?Why: These results decide eligibility for targeted therapy, immunotherapy, and trials.
- Which subtype is my cancer, and does that change the recommended treatment?Why: Recognised subtypes for this cancer include Buccal mucosa squamous cell carcinoma, Gingivobuccal sulcus and lower alveoluscancer, Retromolar trigone cancer.
- Is germline (inherited) genetic testing recommended for me or my family?Why: Inherited variants can change treatment and matter for relatives.
Screening in high-risk populations
- For my situation (screening in high-risk populations), which of the standard options do you recommend and why?Why: Guideline options include: Visual oral examination by trained health workers for tobacco and alcohol users (Kerala trial); treatment of leukoplakia and management of oral submucous fibrosis.
- How do the results of Kerala oral cancer visual screening trial (Trivandrum) apply to someone like me?Why: Trial populations differ from individual patients; ask how closely you match.
Resectable disease
- For my situation (resectable disease), which of the standard options do you recommend and why?Why: Guideline options include: Wide excision with marginal or segmental mandibulectomy as needed, elective or therapeutic neck dissection (Tata Memorial trial), and free-flap reconstruction.
- How do the results of Elective vs therapeutic neck dissection in node-negative oral cancer (Tata Memorial) apply to someone like me?Why: Trial populations differ from individual patients; ask how closely you match.
Borderline resectable (masticator space involvement)
- For my situation (borderline resectable (masticator space involvement)), which of the standard options do you recommend and why?Why: Guideline options include: Induction docetaxel-cisplatin-fluorouracil to shrink technically unresectable tumours, then surgery in responders (Tata Memorial practice); chemoradiation otherwise.
- Am I a candidate for Docetaxel, Cisplatin, Fluorouracil (5-FU), and what side effects should I expect?Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
After surgery
- For my situation (after surgery), which of the standard options do you recommend and why?Why: Guideline options include: Postoperative radiotherapy for advanced stage, perineural invasion or nodes; cisplatin chemoradiation for extranodal extension or positive margins.
- Am I a candidate for Cisplatin, and what side effects should I expect?Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
Palliative and recurrent disease
- For my situation (palliative and recurrent disease), which of the standard options do you recommend and why?Why: Guideline options include: Oral metronomic methotrexate with celecoxib; low-dose nivolumab added where affordable; metronomic tablets with paclitaxel-carboplatin (METRO PLUS); pembrolizumab where available.
- Am I a candidate for Methotrexate, Nivolumab, Pembrolizumab, and what side effects should I expect?Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of Oral metronomic chemotherapy vs intravenous cisplatin (Tata Memorial) and Low-dose nivolumab plus metronomic chemotherapy (Tata Memorial) apply to someone like me?Why: Trial populations differ from individual patients; ask how closely you match.
Prevention
- For my situation (prevention), which of the standard options do you recommend and why?Why: Guideline options include: Smokeless tobacco and areca nut cessation, gutka bans, and oral screening in high-risk people.
Any stage
- Are there clinical trials I could join, for example of Low-dose nivolumab plus metronomic chemotherapy (Tata Memorial), METRO PLUS (Tata Memorial Centre, Varanasi), Oral cancer visual screening, NIVOPOSTOP (GORTEC 2018-01)?Why: Trials are how the next standard of care is set; asking early keeps options open.
- Would a second opinion at a high-volume centre change anything, and can you help arrange it?Why: Rare or high-stakes decisions benefit from a centre that treats many similar patients.
- What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?Why: Supportive care improves quality of life and helps patients complete treatment.
- I read that “Late presentation and rising incidence as areca nut and gutka use spread”. How does that affect my plan?Why: Open problems are where trials and second opinions matter most.
- I read that “Access to pembrolizumab, cetuximab and radiotherapy machines outside big cities”. How does that affect my plan?Why: Open problems are where trials and second opinions matter most.
Newly diagnosed? Read the first 60 days with Buccal mucosa and gingivobuccal cancer, then print the one-page appointment sheet with room for the answers.
Print this page for your appointment (your browser's print command). These prompts are for discussion; your clinical team knows your case.
Direct links plus the targets, companies, and technologies of this cancer's products.
technologies
6targets
1drugs
6companies
4institutions
3terms
1trials
6Latest papers
topQuery for this cancer: (TITLE:"Buccal mucosa and gingivobuccal cancer" OR ABSTRACT:"Buccal mucosa and gingivobuccal cancer" OR TITLE:"oral cancer in India" OR ABSTRACT:"oral cancer in India" OR TITLE:"Gingivobuccal complex cancer" OR ABSTRACT:"Gingivobuccal complex cancer" OR TITLE:"Cheek cancer" OR ABSTRACT:"Cheek cancer" OR TITLE:"Betel quid-associated oral cancer" OR ABSTRACT:"Betel quid-associated oral cancer" OR TITLE:"Indian oral cancer" OR ABSTRACT:"Indian oral cancer") AND (treatment OR therapy OR trial OR survival OR diagnosis). Results are unfiltered search hits about Buccal mucosa and gingivobuccal cancer (oral cancer in India), not a curated reading list.
Similar pages
not linked directly; found by shared links- CancerOral tongue and floor of mouth cancer
Shares Oral cancer visual screening, Elective vs therapeutic neck dissection in node-negative oral cancer (Tata Memorial), NIVOPOSTOP (GORTEC 2018-01), Oral cavity cancer (mouth and tongue) and the tags subtype-page, head-and-neck.
- CancerLip cancer
Shares Oral cavity cancer (mouth and tongue), Smoking cessation in cancer patients, Chemoradiation (chemoradiotherapy, CRT), Cisplatin and the tags subtype-page, head-and-neck.
- CancerHypopharyngeal cancer
Shares NIVOPOSTOP (GORTEC 2018-01), Smoking cessation in cancer patients, Chemoradiation (chemoradiotherapy, CRT), Fluorouracil (5-FU) and the tags subtype-page, head-and-neck.
- CancerHPV-negative head and neck squamous cell carcinoma (including HPV-negative oropharyngeal cancer)
Shares NIVOPOSTOP (GORTEC 2018-01), Oral metronomic chemotherapy vs intravenous cisplatin (Tata Memorial), Low-dose nivolumab plus metronomic chemotherapy (Tata Memorial), Smoking cessation in cancer patients and the tags subtype-page, head-and-neck.
- CancerSalivary duct carcinoma
Shares Chemoradiation (chemoradiotherapy, CRT), Docetaxel, Cisplatin, IMRT / IGRT (modern external beam) and the tags subtype-page, head-and-neck.
- CancerMucoepidermoid carcinoma
Shares Chemoradiation (chemoradiotherapy, CRT), Cisplatin, IMRT / IGRT (modern external beam), Pembrolizumab and the tags subtype-page, head-and-neck.
- CancerHPV-positive oropharyngeal cancer
Shares Chemoradiation (chemoradiotherapy, CRT), Cisplatin, IMRT / IGRT (modern external beam), Pembrolizumab and the tags subtype-page, head-and-neck.
- CancerAdenoid cystic carcinoma
Shares Cisplatin, IMRT / IGRT (modern external beam) and the tags subtype-page, head-and-neck.